Boehringer Ingelheim achieves broad-based growth in H1 2016

Boehringer Ingelheim has achieved broad-based growth and met a number of key strategic targets during the first half of 2016.

The company's half-year net sales came to approximately 7.3 billion euros (6.1 billion pounds), representing a year-on-year increase of two percent in currency-adjusted terms, or down by one percent in terms of euros.

Excluding the US generics business Roxane, which was sold in February, currency-adjusted growth in the first six months of the financial year rose to five percent, or one percent in euro terms.

Growth was achieved across all of Boehringer Ingelheim's core business units, while a number of key milestones were achieved, including the agreement of an asset swap deal to exchange Sanofi's animal health business Merial with Boehringer Ingelheim's consumer healthcare business.

The firm has also restructured its human pharmaceutical and innovation corporate board divisions to drive greater efficiency.

Hubertus von Baumbach, chairman of the board of managing directors at Boehringer Ingelheim, said: "Future success in our core business prescription medicines will depend on how successfully we can establish ourselves as a partner of choice – from preclinical research right through to patients."